$CRDF

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Cardiff Oncology Appoints Leila Alland, MD, as Interim Chief Medical Officer Seasoned oncology executive brings extensive clinical development expertise and a track record of advancing innovative cancer therapies SAN DIEGO, Calif., October 27, 2026 — Cardiff Oncology

Cardiff Oncology (CRDF) appointed Leila Alland, MD, as interim Chief Medical Officer. The company's Phase 2 trial for onvansertib in metastatic colorectal cancer shows median progression-free survival not yet reached. A Phase 3 study is planned for Q1 2027. Alland has extensive experience in oncology drug development.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders On October 22, 2026, Cardiff Oncology, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). A total of 48,084,246 shares of common stock, constituting a quorum, were represented in per

Cardiff Oncology (CRDF) received FDA Orphan Drug Designation for onvansertib to treat chronic myelomonocytic leukemia (CMML). The drug showed preliminary efficacy in a Phase 1 trial, with benefits including platelet response and stable disease. Orphan Drug Designation offers tax credits, fee exemptions, and market exclusivity. CRDF is developing onvansertib for other cancers as well.

PDS Biotech (PDSB) announced a $22.55M PIPE financing for late-stage cancer drug development, shares up 50.64%. Avaí Bio (AVAI) completed cell bank testing, shares up 14.29%. Clene (CLNN) priced a $4M offering, shares up 25.25%. NurExone (NRX.V) partnered with NanoPass, shares up 8.06%. Cardiff Oncology (CRDF) settled a licensing dispute, shares up 4.58%. Indaptus (INDP) shares surged 16.88% without specific news.

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement Under the terms of the Amendment, all disputed issues are resolved SAN DIEGO and NERVIANO, Italy, September 14, 2026 — Cardiff Oncology, Inc. (NASDAQ: CRDF) (“Cardiff”) and Ne

Cardiff Oncology, Inc. (CRDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated m

Investing.com reported U.S. insider trading for July 16, 2026. Major buys included Boundless Bio (63,969 shares, about $155.6k), ADIAL Pharmaceuticals (3,233 shares, $8,690), FIS (1,386 shares, $57.4k) and Cardiff Oncology (34,364 shares plus warrants). Major sells included Celcuity (3.1M shares, about $317.8M), Arista Networks (300k shares, about $54.2M), Butterfly Network (4.0M shares, about $29.4M), CoreWeave (307,692 shares, about $24.8M) and Venture Global (555,556 shares, about $14.3M).

PACE GARY W purchased 687,285 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 ($1.00M total) on 2026-07-14.

Mohindru Mani (Chief Executive Officer) purchased 34,364 shares of Cardiff Oncology, Inc. (CRDF) at $1.46 on 2026-07-14.